Analyst Views Mixed as Evonik Faces Softer Outlook Amid Valuation Adjustments and Strategic Moves

Key Takeaways

• Aggressive cost optimization and a shift to specialty chemicals are set to strengthen margins and align with rising demand for sustainable solutions.
  
• Expanded production in key plants and focus on healthcare, nutrition, and biopharma position the company for stable growth aided by regulatory and demographic trends.
  
• Heavy dependence on cyclical sectors, ongoing exposure to low-margin commodities, and external macroeconomic and regulatory risks threaten Evonik's revenue stability and margin expansion prospects.

Catalysts

Produces and sells specialty chemicals in the Asia-Pacific, Europe, the Middle East, Africa, Central and South America, and North America.

• Strategic cost optimization programs-including significant headcount reductions and site closures (notably in Silica)-are expected to lower operating costs and support net margin expansion throughout 2025 as savings become fully visible by year-end.
  
• Ramp-up of new production capacities, especially the alkoxides plant in Singapore and the RNA/lipids plant in Slovakia, positions the company to capture incremental volume opportunities tied to sustainable materials and biopharmaceutical applications, supporting medium-term revenue growth.
  
• Strong resilience and operational improvements in Healthcare and Nutrition segments, coupled with contracted year-end sales, are set to benefit from demographic shifts and rising healthcare/nutrition demands, resulting in more stable and recurring earnings streams.
  
• Ongoing portfolio shift towards high-margin specialty chemicals and away from commoditized businesses aligns with strict regulatory trends and customer demands for eco-friendly, high-value additives, supporting both top-line growth and structural margin uplift over the long term.
  
• Increasing support from EU decarbonization and circular economy initiatives is likely to benefit Evonik's innovation funding and operational cost base (through incentives and energy transition support), providing structural tailwinds for sustainable earnings growth.

Evonik Industries Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Evonik Industries's revenue will grow by 2.6% annually over the next 3 years.
• Analysts assume that profit margins will increase from 1.1% today to 3.9% in 3 years time.
• Analysts expect earnings to reach €575.7 million (and earnings per share of €1.23) by about May 2029, up from €157.0 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as €838.0 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 16.7x on those 2029 earnings, down from 50.5x today. This future PE is lower than the current PE for the GB Chemicals industry at 28.6x.
• Analysts expect the number of shares outstanding to grow by 0.31% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.09%, as per the Simply Wall St company report.

Risks

• Persistent weak demand and low consumer confidence across key end-markets, combined with limited visibility on macroeconomic improvement, exposes Evonik to revenue volatility and constrains earnings growth in the medium to long term.
  
• Heavy reliance on cyclical sectors such as construction and automotive makes Evonik vulnerable to economic downturns and delays in sectoral recovery, hampering revenue stability and profit margins.
  
• Continued exposure to the underperforming C4 and commodity chemicals business, with no clear timeline for strategic exit, could limit Evonik's ability to accelerate its shift toward higher-margin specialty products, restraining future margin expansion and top-line growth.
  
• Ongoing geopolitical tensions and evolving trade policies (e.g., tariffs, deglobalization pressures) create supply chain risks and input cost uncertainty, which may increase costs or disrupt operations, thereby impacting net margins and overall global competitiveness.
  
• Over-optimism regarding decarbonization incentives and EU action plans may be misplaced if regulatory burdens, higher compliance costs, and market shifts toward bio-based products accelerate, potentially outpacing Evonik's internal transformation efforts and weighing on long-term profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of €17.23 for Evonik Industries based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €20.4, and the most bearish reporting a price target of just €14.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €14.8 billion, earnings will come to €575.7 million, and it would be trading on a PE ratio of 16.7x, assuming you use a discount rate of 6.1%.
• Given the current share price of €17.01, the analyst price target of €17.23 is 1.3% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.